MedTrace Logo

Study to Investigate the Ability of [11C]Donepezil PET to Image the Parasympathetic Nervous System

NCT01877538 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 7

Last updated 2016-03-23

Study results available
· View outcomes & findings →

Summary

AIM: To validate the tracer \[11C\]donepezil for use in the parasympathetic nervous system.

MATERIALS AND METHODS: The Investigators will include 7 healthy males aged 45-75 in our study. The participants will receive a careful medical examination, including a neurological examination, as part of the inclusion process. The subjects also have an MRI scan of the brain. PET/CT scans with \[11C\]donepezil are conducted. Six subjects will receive two PET/CT scans - once for the upper abdominal region and once for the head region two evaluate dynamic binding characteristics of the tracer in internal organ. Additionally, one single subject will receive 5 consecutive whole body PET scans to estimate radioactive dosimetry of this tracer.

PERSPECTIVES: The study will potentially result in the development of a PET ligand for imaging the parasympathetic nervous system. This will have applications for research in Parkinson's disease, diabetes, heart disease and other disorders, in which the autonomic nervous system is involved

Conditions

Interventions

OTHER

[11C]donepezil PET

Positron Emission Tomography (PET) imaging of acetylcholinesterase with the ligand \[11C\]donepezil

Sponsors & Collaborators

  • Lundbeck Foundation

    collaborator OTHER

  • Per Borghammer

    lead OTHER

Principal Investigators

  • Per Borghammer, MD,PhD · Dept. of Nuclear Medicine & PET Center, Aarhus University Hospital, Aarhus, Denmark

Eligibility

Min Age
45 Years
Max Age
75 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-05-31
Primary Completion
2013-07-31
Completion
2013-07-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01877538 on ClinicalTrials.gov